Paul Stoffels is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in resource-poor settings. Previously, as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the R&D pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines. Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined J&J in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition. Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.